Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

VINCRISTINE SULFATE

All injection strengths: general benefit

Other products in the same Health Canada class (L01C) — coverage varies; not interchangeable

  • Etoposide (Vepesid): general benefit

Vincristine Sulfate · DIN 02143305 · 1mg/mL · injection solution

General benefitMarketed · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Vincristine Sulfate · DIN 02143305 Manufacturer: Novopharm Ltd.; listing date 1996-10-01 Health Canada: Marketed since 2014-04-12 · brand VINCRISTINE SULFATE INJECTION · ATC L01CA02 VINCRISTINE · form Solution · route Intravenous · ingredients VINCRISTINE SULFATE 1 MG/ML · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Vincristine Sulfate: Formulary list price $30.6000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $30.6000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19756 · Verify on the e-Formulary ↗ (DIN 02143305)

Source record
DIN 02143305: Vincristine Sulfate Raw flags: sec3=Y Item: 100000049; group id 189; item number 0347; lccId None; manufacturer id NOP Source form: Inj Sol; strength: 1mg/mL Recorded listing: General benefit Source prices (unrounded): $30.6000; ministry $30.6000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02143305 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19756
Interchangeable products
Oncovin · DIN 00611182 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered

Matched class: 10:00 ANTINEOPLASTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSERELIN ACETATE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LETROZOLE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE Some products covered without a code (check the product listing): BICALUTAMIDE, CYCLOPHOSPHAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, TAMOXIFEN CITRATE 10:00 ANTINEOPLASTIC AGENTS

ETOPOSIDE

· 1 products · General benefit · strengths: 50mg · Cap

ABIRATERONE ACETATE

· 18 products · General benefit · strengths: 250mg, 500mg · Tab

ALTRETAMINE

· 1 products · General benefit · strengths: 50mg · Cap

ANASTROZOLE

· 17 products · General benefit · strengths: 1mg · Tab

BICALUTAMIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 50mg · Tab

BUSERELIN ACETATE

· 4 products · General benefit · strengths: 6.3mg, 9.45mg, 1mg/mL · Implant Kit, Inj Sol-5.5mL Pk, Nas Sp-10mL Pk

BUSULFAN

· 1 products · General benefit · strengths: 2mg · Tab

CAPECITABINE

· 15 products · General benefit · strengths: 150mg, 500mg · Tab

CHLORAMBUCIL

· 1 products · General benefit · strengths: 2mg · Tab

CYCLOPHOSPHAMIDE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 25mg, 50mg · Tab

CYPROTERONE ACETATE

· 4 products · General benefit · strengths: 50mg · Tab

DAUNORUBICIN

· 1 products · General benefit · strengths: · Inj Pd-20mg Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 10:00 and 34 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE VINCRISTINE SULFATE INJECTION is indicated in the treatment of acute leukemia. It has also been shown to be useful in combination with other oncolytic agents in Hodgkin's disease, soft-tissue sarcoma, bony-tissue sarcoma, sarcomas of specialized structures, breast cancer, small cell cancer of the lung, cancer of the uterine cervix, malignant melanoma, colorectal cancer, non-Hodgkin's lymphoma and Wilms' tumor. Current practices of cancer chemotherapy involve the simultaneous use of several agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. It is rarely possible to achieve equally good results with single agent treatment. Thus, vincristine is often chosen as part of polychemotherapy because of lack of significant bone marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy). Multiple agent regimens have been developed for the treatment of a variety of malignant disorders in children. Pediatric patients with neuroblastoma, osteogenic sarcoma, Ewing's sarcoma, rhabd… https://pdf.hres.ca/dpd_pm/00067738.PDF PM date: October 12, 2022 Source product: VINCRISTINE SULFATE INJECTION; DIN 02143305; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.